Absci appoints Mary Szela to Board effective July 7, 2025; grants 178,400 share option

Absci Corp

Mary Szela appointed as Class III director; board expanded from six to seven members.
Receives initial option grant for 178,400 shares at closing price on grant date, vesting monthly over three years.
Will receive $40,000 annual cash retainer under Non-Employee Director Compensation Policy.
Szela currently serves as CEO, President and Director of Trisalus Life Sciences.

item 5.02

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.